Skip to content

GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM)

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-511452-40-00
Acronym
GCAR-7213
Enrollment
120
Registered
2024-07-16
Start date
2025-09-12
Completion date
Unknown
Last updated
2025-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oncology - Glioblastoma (GBM)

Brief summary

Overall Survival defined from the time of randomization to death from any cause

Detailed description

Progression-Free Survival defined as the time from randomization to clinically determined progression or death from any cause, Tumor Response: complete response, partial response, progressive disease, stable disease, Duration of Response: - Complete Response and Partial Response defined as time from date of response to date of clinically determined disease progression or death from any cause

Interventions

Sponsors

Global Coalition For Adaptive Research Inc.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Overall Survival defined from the time of randomization to death from any cause

Secondary

MeasureTime frame
Progression-Free Survival defined as the time from randomization to clinically determined progression or death from any cause, Tumor Response: complete response, partial response, progressive disease, stable disease, Duration of Response: - Complete Response and Partial Response defined as time from date of response to date of clinically determined disease progression or death from any cause

Countries

France, Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026